Ocular Therapeutix Secures $23,800,000 Series D Round

  • Feed Type
  • Date
    1/28/2013
  • Company Name
    Ocular Therapeutix
  • Mailing Address
    36 Crosby Dr. Bedford, MA 01730
  • Company Description
    Ocular Therapeutix, Inc. is a privately held company focused on the development and commercialization of ophthalmic therapeutic products using its proprietary hydrogel technology to address unmet or underserved needs in ophthalmology and ophthalmic surgery.
  • Website
    http://www.ocutx.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $23,800,000
  • Transaction Round
    Series D
  • Proceeds Purposes
    Ocular Therapeutix will use the funds to further advance development activities and implementation of clinical trials for its sustained release drug programs, including travoprost for the treatment of glaucoma, and dexamethasone for the resolution of post-operative inflammation and pain. The funds will also be used to support U.S. commercial launch efforts and to develop sustained release therapies for retinal diseases in collaboration with pharma partners.
  • M&A Terms
  • Venture Investor
    Polaris Venture Partners
  • Venture Investor
    Versant Ventures
  • Venture Investor
    SV Life Sciences
  • Venture Investor
    Ascension Health Ventures